--- title: 'Senior Director, Biostatistics at Spyre Therapeutics' canonical: 'https://feeny.ai/job/senior-director-biostatistics-spyre-therapeutics-united-states-ehz60g8kxfxv' type: 'job' last_seen: '2026-09-15' --- # Senior Director, Biostatistics at Spyre Therapeutics - **Company:** Spyre Therapeutics - **Location:** United States - **Work type:** remote - **Posted:** 2026-07-03 - **Last confirmed live:** 2026-09-15 - **Apply:** https://job-boards.greenhouse.io/spyretherapeutics/jobs/5282836008 ## Job description Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, and IL-17A/F as well as rational combination programs. ## Role Summary The Sr. Director of Biostatistics will provide leadership and strategic input for clinical development programs assigned. The selected individual will be responsible for statistical activities supporting clinical trials, including contributing to trial designs, authoring statistical sections of protocols, preparing statistical analysis plans, and reviewing and interpreting the analysis of clinical trial data. This is a hands-on role where you will interact with internal and external cross-functional study teams, support interactions with Health Authorities globally, conduct ad-hoc analyses, and manage biometrics vendors in preparing analysis files, performing statistical analyses, and delivering analysis results and data files. ## Key Responsibilities - Lead the biometrics team including statistician, data manager, and statistical programmer at a program level - Provide statistical input to strategic planning, study design, protocol development, sample size calculation, CRF, Results Interpretation, clinical study report, and address questions from regulatory agencies - Promote research of advanced and innovative statistical methods to increase probability of success of clinical studies - Author and develop SAPs, and work with extended team or vendor in developing specification for derived variables, templates of statistical tables, figures, and listings - Provide guidance to study team on all aspects of statistical activities; collaborate closely with data manager to ensure high-quality data - Participate in cross-functional study-related activities; Work collaboratively with Clinical Development, Clinical Operations, Clinical Data Managers, Pharmacovigilance ＆ Epidemiology, Regulatory, Project Management, Translational Medicine, and other staff and vendors to meet project deliverables and timelines - CRO / Vendor Oversight: Establish procedures through regular interaction, setting expectations on deliverables and timelines. Ensure deliverables are accurate and delivered according to timelines - Global Health Authority Interaction: Contribute to documents submitted to Health Authorities globally by providing input for the interaction or by writing the interaction document. May participate in meetings or teleconferences with Health Authorities - Coordinate with internal and external team members to prepare the statistical analyses for IB, DSUR updates, periodic safety updates, and other ad hoc analyses - Build and develop efficient biostatistical processes and standards, when appropriate Ideal Candidate - PhD Degree in Biostatistics, Statistics, or a related field with at least 10-12 years of experience in biostatistics within the pharmaceutical, biotech, or CRO industry. - Strong knowledge of statistical methodologies and their application in clinical trials and health research. Working knowledge of Bayesian methodology is preferred. - Experience with regulatory submissions and interactions with regulatory agencies. - Proficiency in statistical software (e.g., SAS, R) and data management systems. - Experience with CDSIC including SDTM, ADaM, CDASH - Successful track record of working independently in a matrixed organization and providing solutions to emerging problems. - Excellent communication and interpersonal skills, along with organizational skills. - Ability to work collaboratively in a multidisciplinary team environment. ## What We Offer - Opportunity to work in a fast-paced, dynamic environment where you help shape the culture of our young company, contribute broadly to advance meaningful medicines, and learn quickly. - Market competitive compensation and benefits package, including base salary, performance bonus, equity grant opportunities, health, welfare & retirement benefits. - Unlimited PTO - Two, one-week company-wide shutdowns each - Commitment to provide professional development opportunities. - Remote working environment with frequent in-person meetings to address complex problems and build relationships. The expected salary range offer for this role is $ 275,000 to $290,000. Actual pay offered may vary depending on job related knowledge, experience, education, and geographic location. As an equal opportunity employer, Spyre is committed to a diverse workforce. Employment decisions regarding recruitment and selection will be made without discrimination based on race, color, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression, veteran status, or other non-job-related characteristics or other prohibited grounds specified in applicable federal, state and local laws. We also embrace differences in experience and background, and welcome diversity of opinions and thought with active recruitment designed to create a stronger and better Spyre that is focused on developing life-changing products for patients. Spyre Therapeutics, along with other biotech companies, has become aware of a surge in email scams targeting prospective job candidates within our industry. Please be aware that official recruiters at Spyre Therapeutics only use email addresses with the domain “@spyre.com.” We want to also emphasize that we never request candidates to make any purchases or divulge sensitive personal information via email. Please also be aware that all job postings will be listed on our website at spyre.com/careers/. ## About Spyre Therapeutics ## Company Overview - **One-liner**: Spyre Therapeutics is a clinical-stage biotechnology company developing next-generation antibody therapies and rational combinations to elevate the standard of care for inflammatory bowel disease (IBD) and other immune-mediated diseases. - **Entity Type**: Public (NASDAQ: SYRE [ir.spyre.com](https://ir.spyre.com/overview)) - **Headquarters**: Not publicly available (company operates 100% remote with frequent in-person meetings [job-boards.greenhouse.io](https://job-boards.greenhouse.io/spyretherapeutics)) - **Founded**: Not publicly available - **Founders**: Not publicly available ## Core Business - **Primary industry/industries**: Biotechnology / Biopharmaceuticals / Immunology - **Target customers**: B2B (partners, healthcare providers, payers); primarily focused on patients with IBD (Crohn’s disease, ulcerative colitis) and other immune-mediated conditions - **Mission or purpose statement**: “Develop potentially best-in-class therapeutics for people living with IBD” by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations [spyre.com](https://www.spyre.com/) ## Products & Services Spyre’s pipeline consists of investigational extended half-life antibodies targeting validated mechanisms, designed for subcutaneous administration and potentially improved efficacy and convenience: - **SPY001 (α4β7 integrin inhibitor)**: Phase 3-ready anti-integrin antibody with extended half-life; targeting gut-selective inflammation control [spyre.com](https://www.spyre.com/pipeline) - **SPY120 (TL1A antibody)**: Phase 1/2 anti-TL1A antibody targeting fibrostenotic and inflammatory pathways in IBD [spyre.com](https://www.spyre.com/pipeline) - **SPY130 (IL-23 antibody)**: Phase 1/2 anti-IL-23 p19 antibody targeting a validated and highly successful mechanism in IBD [spyre.com](https://www.spyre.com/pipeline) - **SPY002 (α4β7 + TL1A) and SPY003 (α4β7 + IL-23)**: Rational combination programs designed to deliver more complete disease control and greater durability than monotherapy ## Market Standing - **Valuation/Market Cap**: Not explicitly stated; recent public offering raised substantial capital - **Key Metric**: **Total Funding via Public Offering**: $463.5 million gross proceeds from a public offering and full exercise of underwriters’ option, announced May 1, 2026 (upsized from $403.0M) [ir.spyre.com](https://ir.spyre.com/overview) - **Notable Investors/Partners**: The company is publicly traded; institutional and retail investors participated in the offering. Partnership and investor details are disclosed in SEC filings. - **Growth Signals**: - Announced positive **SPY001 Part A Induction Results** on April 14, 2026, demonstrating proof-of-mechanism [ir.spyre.com](https://ir.spyre.com/overview) - Raised $463.5M in a single public offering in May 2026, signaling strong institutional confidence - Pipeline advancing into Phase 2 and Phase 3 programs across multiple antibody formats - Company is rapidly expanding its R&D and clinical capabilities ## Competitive Advantages - **Rational Combination Strategy**: Spyre is one of the few companies pioneering concurrent targeting of α4β7 with TL1A or IL-23 in a single therapeutic program, potentially offering superior efficacy over single-target biologics - **Extended Half-Life Antibody Engineering**: All pipeline antibodies are engineered for longer dosing intervals, which could improve patient adherence and convenience - **100% Remote-First Model**: Operates a fully remote team with periodic in-person gatherings, allowing access to top talent across geographies without requiring relocation - **Deeply Validated Biology**: All three primary targets (α4β7, TL1A, IL-23) are clinically validated in IBD, derisking the pipeline ## Strategic Focus - Advance **SPY001** into Phase 3 trials for IBD - Progress **SPY120** and **SPY130** through Phase 1/2 dose optimization and proof-of-concept studies - Generate clinical data for the **rational combination programs (SPY002, SPY003)** to demonstrate additive/synergistic benefit - Leverage the significant capital raise to expand clinical operations, manufacturing, and pipeline expansion ## Why Work Here - **100% Remote-First Culture**: Spyre is fully remote with “frequent all team, in-person meetings to build relationships and problem solve” [job-boards.greenhouse.io](https://job-boards.greenhouse.io/spyretherapeutics) - **Generous Time Off**: Unlimited PTO plus two one-week company-wide shutdowns each year - **Competitive Compensation**: Market-competitive base salary, performance bonus, and equity grant opportunities - **Comprehensive Benefits**: Health, welfare, and retirement benefits included - **Fast-Paced Startup Environment**: Opportunities to “wear multiple hats, learn quickly, and help shape the culture of our young company” - **Mission-Driven**: Direct impact on improving the lives of millions of IBD patients. The team is described as “collaborative and interdisciplinary” [spyre.com](https://www.spyre.com/careers) - **Transparent and Accessible Leadership**: Company updates and financial results are shared regularly; recent events include public webcasts and presentations ## Sources 1. [spyre.com](https://www.spyre.com/) 2. [ir.spyre.com](https://ir.spyre.com/overview) 3. [job-boards.greenhouse.io](https://job-boards.greenhouse.io/spyretherapeutics) 4. [spyre.com/careers](https://www.spyre.com/careers) 5. [spyre.com/pipeline](https://www.spyre.com/pipeline) ## Other roles at Spyre Therapeutics - [Vice President, Clinical Development](https://feeny.ai/job/vice-president-clinical-development-spyre-therapeutics-united-states-fjdcwr86nqax) — United States - [Senior Director, Biostatistics](https://feeny.ai/job/senior-director-biostatistics-imvt-corporation-remote-swdw529e6zxr)